Nanopatterned Human iPSC-Based Model of a Dystrophin-Null Cardiomyopathic Phenotype

Cellular and Molecular Bioengineering

Volumn 8, Issue 3, 2015, Pages 320-332

  Macadangdang, Jesse ^a,d   Guan, Xuan ^b,c,d   Smith, Alec S T ^a   Lucero, Rachel ^a   Czerniecki, Stefan ^c,d   Childers, Martin K ^c,d   Mack, David L ^c,d   Kim, Deok Ho ^a,d  

^a University of Washington   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytoskeletal alignment; Duchenne muscular dystrophy; FRAP; Stem cell derived cardiomyocytes

Indexed keywords

DYSTROPHIN;

ACTIN FILAMENT; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MUSCLE CONTRACTION; NANOFABRICATION; NANOTECHNOLOGY; NANOTOPOGRAPHY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL;

EID: 84939576089     PISSN: 18655025     EISSN: 18655033     Source Type: Journal    
DOI: 10.1007/s12195-015-0413-8     Document Type: Article

References (43)

1. Adamo, C. M., et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. 107:19079–19083, 2010.
2. Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823, 2013.
3. Deconinck, N., and B. Dan. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36:1–7, 2007.
4. Du, C.-K., et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ. Res. 101:185–194, 2007.
5. Egashira, T., et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 95:419–429, 2012.
6. Ervasti, J. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease 1772:108–117, 2007.
7. Feinberg, A. W., et al. Controlling the contractile strength of engineered cardiac muscle by hierarchal tissue architecture. Biomaterials 33:5732–5741, 2012.
8. Finsterer, J., and L. Cripe. Treatment of dystrophin cardiomyopathies. Nat. Rev. Cardiol. 11:168–179, 2014. doi:10.1038/nrcardio.2013.213.
9. Gordon, B. S., D. A. Lowe, and M. C. Kostek. Exercise increases utrophin protein expression in the mdxmouse model of Duchenne muscular dystrophy. Muscle Nerve 49:915–918, 2014.
10. Guan, X., et al. Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. Stem Cell Res. 12:467–480, 2014.
11. Hansen, A., et al. Development of a drug screening platform based on engineered heart tissue. Circ. Res. 107:35–44, 2010.
12. Hirt, M. N., A. Hansen, and T. Eschenhagen. Cardiac tissue engineering: state of the art. Circ. Res. 114:354–367, 2014.
13. Itzhaki, I., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature Nature Publishing Group 471:225–229, 2011.
14. Kim, D.-H., et al. Nanoscale cues regulate the structure and function of macroscopic cardiac tissue constructs. Proc. Natl. Acad. Sci. 107:565–570, 2010. doi:10.1073/pnas.0906504107.
15. Kim, D.-H., et al. Nanopatterned cardiac cell patches promote stem cell niche formation and myocardial regeneration. Integr Biol 4:1019, 2012.
16. Kimura, A. Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J. Hum. Genet. Nat. Publ. Group 55:81–90, 2010.
17. Kshitiz, et al. Control of stem cell fate and function by engineering physical microenvironments. Integr. Biol. 4:1–20, 2012.
18. Lahti, A. L., et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Models Mech. 5:220–230, 2012.
19. Lee, J., M.E. Razu, X. Wang, C. Lacerda, and J. Kim. Biomimetic cardiac microsystems for pathophysiological studies and drug screens. J. Lab. Autom. 1–24, 2014.
20. Leung, D. G., et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann. Neurol. 76:541–549, 2014.
21. Liang, P., et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127:1677–1691, 2013.
22. Lozano, R., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128, 2012.
23. Macadangdang, J., et al. Capillary force lithography for cardiac tissue engineering. JoVE 88:e50039, 2014.
24. Matsa, E., et al. Drug evaluation in cardiomyocytes derived fromhuman induced pluripotent stem cells carrying along QT syndrome type 2 mutation. Eur. Heart J. 32:952–962, 2011.
25. Milde, F., D. Franco, A. Ferrari, V. Kurtcuoglu, D. Poulikakos, and P. Koumoutsakos. Cell Image Velocimetry (CIV): boosting the automated quantification of cell migration in wound healing assays. Integr. Biol. 4:1437, 2012.
26. Mourkioti, F., et al. Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol. 15:895–904, 2013. doi:10.1038/ncb2790.
27. Navarrete, E. G., et al. Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128:S3–S13, 2013.
28. Okada, J. I., et al. Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator. Sci. Adv. 1:e1400142–e1400142, 2015.
29. Rajan, S., et al. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circ. Res. 101:205–214, 2007.
30. Ran, F. A., P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, and F. Zhang. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8:2281–2308, 2013.
31. Roger, V. L., et al. Heart disease and stroke statistics—2012 update: a report from the american heart association. Circulation 125:e2–e220, 2012.
32. Sen, S., M. Tewari, A. Zajac, E. Barton, H. L. Sweeney, and D. E. Discher. Upregulation of paxillin and focal adhesion signaling follows Dystroglycan Complex deletions and promotes a hypertensive state of differentiation. Eur. J. Cell Biol. 90:249–260, 2010.
33. Sipp, D. Challenges in the clinical application of induced pluripotent stem cells. Stem Cell Res. Ther. 1:1–3, 2010.
34. Sun, N., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4:1–14, 2012.
35. Svendsen, C. N. Back to the future: how human induced pluripotent stem cells will transform regenerative medicine. Hum. Mol. Genet. 22:R32–R38, 2013.
36. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872, 2007.
37. Turnbull, I. C., D. K. Lieu, R. A. Li, and K. D. Costa. Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery. Drug Discov. Today Dis. Models 9:e219–e227, 2012.
38. Vunjak-Novakovic, G., et al. Challenges in cardiac tissue engineering. Tissue Eng. 16:169–187, 2010.
39. Wang, G., et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20:616–623, 2014.
40. Warlich, E., et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol. Ther. 19:782–789, 2009.
41. Yang, H. S., et al. Electroconductive nanopatterned substrates for enhanced myogenic differentiation and maturation. Adv. Healthcare Mater. 2015. doi:10.1002/adhm.201500003.
42. Yang, H. S., et al. Nanopatterned muscle cell patches for enhanced myogenesis and dystrophin expression in a mouse model of muscular dystrophy. Biomaterials 35:1478–1486, 2014.
43. Zhang, Y., et al. Urine derived cells are a potential source for urological tissue reconstruction. J. Urol. 180:2226–2233, 2008.